Core Viewpoint - Chewy has shown resilience and growth despite the easing of pandemic restrictions, expanding into new business lines and increasing profitability, although it faces challenges in net income and market competition [1][4][5]. Company Growth - Chewy's sales reached over $9.3 billion in the first nine months of fiscal 2025, marking an 8% increase from the previous year [4]. - The company has diversified its offerings by selling pet pharmaceuticals and providing telehealth services for pets, which contributed to its growth [4]. Financial Performance - Operating income grew by 74% year-over-year during the first three quarters of fiscal 2025, indicating effective cost management [4]. - However, net income for the same period was $184 million, a decline from the previous year, resulting in a net margin decrease from 4.3% to 2% [5]. Valuation Metrics - Chewy's current P/E ratio stands at 55, but it is projected to drop to a forward P/E ratio of 17, which may attract investors [6]. - The forward valuation suggests that Chewy could be undervalued compared to the broader market, potentially allowing it to outperform the S&P 500 [9]. Market Position - Chewy operates with a market cap of $10 billion, which is less than 0.5% of Amazon's size, indicating a more niche market focus [3]. - Despite its growth, Chewy is not expected to reach a stock price of $100 per share in the near term [7].